Company Filing History:
Years Active: 2014
Title: Gal Dela: Innovator in HIV Research
Introduction
Gal Dela is an accomplished inventor based in Kiryat Ono, Israel. He has made significant contributions to the field of HIV research through his innovative work on peptides that interact with the HIV envelope protein gp120. His research aims to enhance the immune response against HIV, which remains a critical challenge in the fight against this virus.
Latest Patents
Gal Dela holds a patent for "Peptides inducing a CD4i conformation in HIV gp120 while retaining vacant CD4 binding site." This novel peptide complex is designed to induce a CD4i conformation in the HIV-1 envelope protein gp120 without occluding the CD4 binding site. The immunogenic properties of this peptide-gp120 complex have shown promise in inducing broadly-neutralizing antibodies when subjects are immunized. The peptide consists of a sequence of 8-20 amino acid residues, featuring a core sequence of Arg-Xaa-Asp-Leu-Pro-Xaa-Trp-Ala, where Xaa can be any amino acid, or certain substitution variants of this sequence.
Career Highlights
Gal Dela is associated with Ramot at Tel Aviv University Ltd., where he continues to advance his research in the field of immunology and HIV. His work is characterized by a commitment to developing innovative solutions that can potentially lead to effective treatments for HIV.
Collaborations
Gal Dela collaborates with Jonathan M. Gershoni, a fellow researcher in the field. Their combined expertise contributes to the advancement of knowledge and innovation in HIV research.
Conclusion
Gal Dela's contributions to HIV research through his innovative peptide technology represent a significant step forward in the quest for effective treatments. His work exemplifies the importance of scientific innovation in addressing global health challenges.